

Efficacy of bupivacaine infiltration for controlling post-tonsillectomy pain, duration of surgery and post-operative morbidities: A systematic review and meta-analysis

JUAN WANG¹, NING WANG¹ and FANGHUA GONG²

Departments of ¹Ear, Nose, Throat, and Head Neck Surgery (III) and ²Nursing, Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Changsha, Hunan 410016, P.R. China

Received June 22, 2020; Accepted October 8, 2020

DOI: 10.3892/etm.2021.9631

Abstract. The objective of the present review and meta-analysis was to evaluate the efficacy of bupivacaine during tonsillectomy in terms of reducing the mean operative procedure duration, post-operative pain and the onset of post-operative morbidities. The Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were followed to perform a systematic literature search using the MEDLINE, Scopus, EMBASE and CENTRAL databases. The present meta-analysis sought to evaluate the efficacy of bupivacaine administered during tonsillectomy as compared to the administration of normal saline. The efficacy of the intervention was evaluated based on pain scores using the visual analogue scale, the duration of the operation and the occurrence of post-operative morbidities. Out of 1,427 records, 15 articles with 729 participants (mean age, 10.2±6.7 years) were included in the study. The present systematic review supported the use of bupivacaine during tonsillectomy at a level of evidence of 1b and confirmed beneficial effects of bupivacaine intervention by demonstrating small to large effect reductions in the visual analog scale score (Hedge's *g*, -1.48), the mean duration of the operative procedure (Hedge's *g*, -1.35) and the incidence of post-operative morbidity (Hedge's *g*, -0.23) in comparison to the placebo groups treated with normal saline. Based on these results, the administration of bupivacaine is recommended during tonsillectomies to reduce the perceived level of pain, the duration of the operation and the post-operative morbidity.

Introduction

Tonsillectomy is a common surgical intervention (1-3). It involves the complete or partial removal of the palatine tonsils primarily to prevent recurring infections and inflammation (4,5). However, the surgical site is a highly vascularized zone and complications are frequent due to unintended trauma during the procedure (6,7). For instance, tonsillectomy is associated with large amounts of blood loss during the operation (8,9) and with subsequent inflammatory responses due to tissue trauma that causes high levels of pain and post-operative morbidities (due to the accumulation of local tissue exudates around the surgical site) (10-12). A high level of edema within 24 h of the operation in the uvula and the palatopharyngeal and palatoglossal areas may interfere with optimal healing and is associated with increased post-operative morbidities (13). In addition, tonsillectomy causes collateral damage to the pharyngeal muscles and exposes nerve endings (tonsillar glossopharyngeal, maxillary trigeminal and lesser palatine nerve branches) (14), leading to post-operative complications such as severe pain, difficulty swallowing or breathing, as well as vomiting and otalgia (13,15,16).

These complications may be reduced with local anesthetic agents such as bupivacaine (17,18). The application of bupivacaine may decrease the onset of post-operative pain by blocking afferent nerve endings through inhibition of voltage-gated Na⁺ channels (19). Furthermore, the anesthetic agent inhibits synaptic N-methyl-D-aspartate receptors (19,20) and has anti-inflammatory properties (21,22). In 2013, Block *et al* (21) also reported that bupivacaine reduces inflammatory activity by inhibiting Ca²⁺ ion signaling and the release of interleukin-1 β in astrocytes, and by interacting with 5-hydroxytryptamine, opioid and glutamate receptors. Similarly, the reduction of vascular permeability by bupivacaine has also been reported to help reduce intra-operative and post-operative complications (23,24). Bupivacaine has been deemed superior to other anesthetic agents such as lidocaine and ropivacaine due to its sustained effects, higher potency and lower toxicity profile (25-27).

Despite the enhanced effectiveness demonstrated by bupivacaine, there is still no consensus regarding its application

Correspondence to: Dr Fanghua Gong, Department of Nursing, Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), 69 Jiefang West Road, Changsha, Hunan 410016, P.R. China
E-mail: gongfh_dr@sohu.com

Key words: anesthesia, tonsillectomy, adenotonsillectomy, bupivacaine, pain

during tonsillectomy to reduce intra-operative and post-operative complications. Certain studies have recommended the administration of bupivacaine during rhinoplasty due to its ability to prevent intra-operative and post-operative complications (28-31). Previous studies, particularly meta-analyses (18), have failed to provide conclusive evidence to support bupivacaine application during tonsillectomies. This lack of agreement has delayed the adoption of a standard protocol for optimal drug interventions during tonsillectomy. The present review includes, for the first time, a detailed analysis of the isolated efficacy of bupivacaine to improve intra-operative factors associated with tonsillectomy such as the duration of the operative procedure. Since the publication of the last meta-analysis on this subject, several high-quality randomized controlled trials (RCTs) have been published, evaluating the efficacy of bupivacaine to improve intra-operative and post-operative morbidities associated with tonsillectomy (28-34,34-36).

The present systematic review and meta-analysis aimed to provide an updated evaluation of the effects of bupivacaine on operative and post-operative outcomes associated with tonsillectomy. Endpoints included the mean perceived level of pain based on the visual analogue scale score, the mean operative procedure duration and the incidence of post-operative morbidities. The present results should help otolaryngologists to make optimal decisions about the best approach to minimize morbidities associated with tonsillectomy procedures.

Materials and methods

Data search strategy. The Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were followed (35). A total of four academic databases (MEDLINE, CENTRAL, EMBASE and Scopus) were searched from inception until April 2020 using the following MeSH key words: 'Tonsillectomy', 'Bupivacaine', '1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide', 'Bupivacain janapharm', 'Bupivacain-RPR', 'Bupivacaina braun', 'Bupivacaine anhydrous', 'Bupivacaine carbonate', 'Bupivacaine hydrochloride', 'Bupivacaine monohydrochloride', 'Bupivacaine monohydrate', 'Buvacaina', 'Carbostesin', 'Dolanaest', 'Marcain', 'Marcaine', 'Sensorcaine', 'Svedocain sin vasoconstr', 'anesthesia', 'anesthetics', 'visual analog scale', 'Children's Hospital of Eastern Ontario pain scale', 'morbidity', 'complications', 'blood loss' and 'post-operative morbidity'. The bibliography of the included studies was subsequently searched for any additional relevant studies. The inclusion criteria for studies were defined as follows: a) Studies that assessed and stated outcomes in a post-operative follow-up assessment; b) studies that were either RCTs, quasi-RCTs, controlled clinical trials, prospective observational trials with established control groups or retrospective trials; c) studies in peer-reviewed scientific journals or conference proceedings; d) studies written in English. To avoid any bias, two reviewers (NW and FG) independently replicated the selection process. The data extracted from the selected studies included the authors' names, patient information (age, sex), variables assessed, country, follow-up duration and outcome measures. Appropriate attempts to contact corresponding authors of relevant articles with incomplete quantitative outcome data were made to obtain additional data.

Quality assessment. The Cochrane risk of bias assessment tool for RCTs was used to evaluate the risk of bias (36). A total of two independent reviewers (NW and FG) appraised the selected studies critically on the basis of their methodology. The reviewers also analyzed each selected study for inadequate randomizations, allocations, selection outcome reports and distributions of allocation as a potential source of bias (37). Data ambiguity was resolved by discussions between the reviewers and a level of evidence analysis was included based on the guidelines of the Centre for Evidence-Based Medicine (38).

Data analysis. Statistical meta-analysis of the encompassed studies was performed using the Comprehensive Meta-analysis version 2.0 software (39). Data for relevant variables were extracted from the selected studies for analysis and mean values were compared between the groups of patients treated with either bupivacaine or normal saline. The statistical meta-analysis was based on the random-effects model (40), in which effect sizes are reported as weighted Hedge's *g* values. Results for weighted effect sizes were categorized as small (≤ 0.2), medium (0.2-0.8) or large (≥ 0.8) (41). I^2 statistics were computed to assess heterogeneity, which was classified as either insignificant (0-25%), modest (25-75%) or considerable ($\geq 75\%$) (42). Sensitivity analysis was performed for studies with considerable sources of heterogeneity (43). Certain results were excluded due to insufficient randomization methods in the studies. For each statistic, 95% confidence intervals (CIs) and the level of heterogeneity were calculated and Duval and Tweedie's trim and fill process and the Egger's test of intercept were used to assess publication bias (44). The number of missing studies that may exist and the possible consequences for the present meta-analysis were estimated. Imputation of asymmetric studies was performed to define an unbiased overall effect. Subsequently, these trimmed effects were refilled in a plot and the combined effect was recalculated. The alpha level was set at 5%.

Results

Study selection. Initial examination of databases resulted in a total of 1,417 studies. After review of the bibliography of relevant studies, 10 additional studies were selected (Fig. 1). After removing duplicate references and applying selection criteria, 15 RCT studies were retained (17,28-34,45-51). The included studies compared the perceived level of pain after tonsillectomy between bupivacaine and normal saline groups (14,17,28-34,45-47,49-51) (12 studies evaluated the perceived level of pain with visual analog scale scores (17,28-31,33,34,47-51) and 2 with the Children's Hospital of Eastern Ontario pain scale scores (45,46). In terms of pain levels, 9 studies (17,28-34,46) reported a significant ($P < 0.05$) reduction and 2 (45,49) an insignificant reduction ($P > 0.05$) with the use of bupivacaine as compared with the use of normal saline during tonsillectomy. Furthermore, three studies reported no differences in the perceived level of pain between the groups (47,50,51). In addition, five of the included studies reported on the incidence of post-operative morbidity after tonsillectomy in both groups, of which 3 studies reported a significant ($P < 0.05$) reduction (33,46,49), 1 reported an insignificant ($P > 0.05$) reduction (34) and one an insignificant increase in the onset of post-tonsillectomy morbidity (for example, adverse




Figure 1. Preferred Reporting Items for Systematic reviews and Meta-Analyses flow chart for the included studies.




Figure 2. Risk of bias (%) within studies according to the Cochrane risk of bias assessment tool for randomized controlled trials.

effects of the operative procedure) (32,33,45,46,49) in patients receiving bupivacaine as compared to those in the placebo group. Finally, four studies compared the mean duration of the tonsillectomy procedure between the bupivacaine and normal saline groups (17,29,31,34) and reported a significant reduction in the mean duration of the procedure for the group receiving bupivacaine as compared to the placebo group.

Risk of bias. Table I and Fig. 2 present the results of Cochrane's risk of bias assessment for the selected RCTs. The general bias

risk in the studies included was rated as low. The highest risk of bias was due to selective reporting and insufficient blinding. A 1b level of evidence was determined for all of the studies based on their described experimental design.

Publication bias. No missing studies on either side of the mean result were identified after applying the trim and fill technique (Fig. 3). The studies that fall out of the funnel area indicate the possibility of bias. In this case, it can be presumed that the asymmetry in our funnel plot is possibly as a result of heterogeneity arising due to differences between study results and methodology (52,53) had earlier stated that heterogeneity can lead to funnel plot asymmetry if it induces a correlation between study sizes and intervention effects. Nevertheless, in the current analysis the random-effects model indicated overall point estimates and 95% CIs for the evaluated strictures as -1.44 (-1.95 to -0.93), respectively. According to the trim and fill procedure report, these values remained unchanged. These values represent the overall effect size of all the parameters in the included studies before the assessment of publication bias. Furthermore, the intercept, i.e. the captured bias according to the Egger's test was $B_0: -7.46$, 95% CI: -14.51 to -0.41 ($P < 0.05$).

Participant information. Data from 710 patients from the studies included in the present analysis were assessed (Table II). Of these, 379 patients (122 females and 167 males) received bupivacaine and 331 patients (130

Table I. Quality of the analyzed studies according to the Cochrane risk of bias assessment tool for randomized controlled trials.

Study	Random sequence generation	Concealment of allocation	Blinding	Blinding of outcome	Incomplete outcome data	Selective reporting	Other biases	Level of evidence	Ref.
Junaid <i>et al</i> (2020)	+	+	+	?	-	+	-	1b	(30)
Abdel Raheem and Farouk (2019)	+	+	-	-	+	+	-	1b	(28)
Tuhanioglu and Erkan (2018)	+	+	+	+	-	-	?	1b	(34)
Haksever <i>et al</i> (2014)	+	+	+	+	+	+	+	1b	(32)
Ergil <i>et al</i> (2012)	+	+	+	+	+	+	+	1b	(29)
Özkiriş <i>et al</i> (2012)	+	+	?	-	+	+	+	1b	(31)
Özmen and Özmen (2011)	+	+	+	+	+	+	+	1b	(33)
Nikandish <i>et al</i> (2008)	+	+	+	+	+	+	+	1b	(17)
Karaaslan <i>et al</i> (2008)	+	+	+	-	+	+	+	1b	(45)
Unal <i>et al</i> (2007)	+	+	+	+	+	-	?	1b	(51)
Akoglu <i>et al</i> (2006)	+	+	+	?	+	+	+	1b	(46)
Kaygusuz and Susaman (2003)	+	+	-	-	+	+	-	1b	(49)
Johansen <i>et al</i> (1996)	+	+	+	+	+	+	-	1b	(48)
Stuart <i>et al</i> (1994)	+	+	+	+	+	-	+	1b	(50)
Jebeles <i>et al</i> (1992)	+	?	?	?	-	-	?	1b	(47)

-, High risk of bias; +, low risk of bias; ?, unclear risk of bias.




Figure 3. Publication bias funnel plot generated by the Duval and Tweedie trim and fill procedure. Each of the analyzed effects is denoted by a circle in the plot. The boundaries of the plot mark the area where 95% of all the effects would reside in the absence of publication bias. The vertical midline denotes the mean standardized effect of zero. The white and black diamond represent the overall effect size, and the adjusted effect size, respectively.

females and 141 males) received normal saline (control group). Furthermore, two studies did not define or mention the patients' sex distributions (28,30). The mean age of all the patients was 9.1±5.6 years. The mean age of the patients in the bupivacaine and the control group was 9.1±6.4 and 8.8±4.9 years, respectively. However, two studies reported only the overall mean age of their sample (28,30).

Post-operative pain. Of the included studies, 15 studies compared the effects on the perceived levels of pain of patients after receiving tonsillectomy between the bupivacaine and the

placebo groups (17,28-34,45-51). An across-group random-effects analysis (Fig. 4) revealed a large negative and significant effect of bupivacaine to reduce the perceived level of pain after tonsillectomy as compared to the effect of normal saline (g, -1.48; 95% CI, -2.08 to -0.87; P<0.01) with negligible heterogeneity (I², 14.8%).

Duration of operation. A total of four studies compared the mean duration of the tonsillectomy procedure between the bupivacaine and control groups (17,29,31,34). An across-group random-effect analysis (Fig. 5) revealed a large negative and significant effect of bupivacaine to reduce the mean duration

Table II. Characteristics of the studies included.

Author, year, (ref.)	Patient age (years)	Sample size (n)	Country	Assessment	Follow-up (hours)	Outcomes
Junaid <i>et al.</i> , 2020 (30)	14.5±7.4 BP: NA NS: NA	180 (83 F, 97 M) BP: 60 (F, M) NS: 30 (F, M)	Pakistan	Visual analog scale	4, 8, 12, 16	Significant reduction in visual analog scale scores in BP as compared to NS.
Abdel and Farouk 2019 (28)	Mean: 8.7 BP: NA NS: NA	60 (31 F, 29 M) BP: 30 (F, M) NS: 30 (F, M)	Egypt	Visual analog scale	1, 4, 8, 24	Significant reduction in visual analog scale scores in BP as compared to NS.
Tuhanioglu and Erkan, 2018 (34)	BP: 30±6 NS: 25±6	BP: 15 (9 F, 6 M) NS: 15 (8 F, 7 M)	Pakistan	Visual analog scale, operating time	0.25, 6, 12, 24, 168	Significant reductions in visual analog scale scores and operating time in BP as compared to NS.
Haksever <i>et al.</i> , 2014 (32)	BP: 6.0±2.9 NS: 6.7±3.6	BP: 40 (20 F, 20 M) NS: 20 (10 F, 10 M)	Turkey	Visual analog scale, postoperative morbidity	1, 5, 13, 17, 21, 24, 48, 72, 96, 120, 144	Significant reduction in visual analog scale scores in BP as compared to NS. Reduced morbidities related to BP as compared to NS.
Ergil <i>et al.</i> , 2012 (29)	BP: 6±2 NS: 6±2	BP: 30 (14 F, 16 M) NS: 30 (15 F, 15 M)	Turkey	Visual analog scale, operation duration	0, 0.15, 0.5, 6, 12, 24	Significant reductions in visual analog scale scores and operating time scores in BP as compared to NS.
Özkiriş <i>et al.</i> , 2012 (31)	BP: 8.1±4.2 NS: 8.1±4.2	BP: 29 (13 F, 16 M) NS: 29 (12 F, 17 M)	Turkey	Visual analog scale, operation duration	1, 4, 8, 16, 24, 48, 72, 96, 120, 144, 168	Significant reduction in visual analog scale scores and operating time scores in BP as compared to NS.
Özmen and Özmen, 2011 (33)	BP: 6.0±3.7 NS: 6.7±3.6	BP: 20 (10 F, 10 M) NS: 20 (11 F, 9 M)	Turkey	Visual analog scale, post-operative morbidity	1, 5, 13, 17, 21, 24, 48, 72, 96, 120, 144	Significant reduction in visual analog scale scores and comorbidities in BP as compared to NS.
Nikandish <i>et al.</i> , 2008 (17)	BP: 10±2.4 NS: 10±2.3	BP: 33 (14 F, 19 M) NS: 36 (17 F, 19 M)	Iran	Visual analog scale, operation duration	1, 2, 4, 6, 8, 12	Significant reduction in visual analog scale scores, operating time score in BP as compared to NS.
Karaaslan <i>et al.</i> , 2008 (45)	BP: 7.0±0.5 NS: 7.4±0.5	BP: 25 (11 F, 14 M) NS: 25 (17 F, 8 M)	Turkey	Children's Hospital of Eastern Ontario pain scale, post-operative morbidity	0.25, 1, 4, 8, 16, 24	Reduction in Children's Hospital of Eastern Ontario pain scale scores in BP as compared to NS. Increased co-morbidities in BP as compared to NS.
Unal <i>et al.</i> , 2007 (51)	BP: 7.5±3.1 NS: 8.2±2.9	BP: 20 (2 F, 18 M) NS: 20 (4 F, 16 M)	Turkey	Visual analog scale	0, 0.08, 0.16, 0.25, 0.5, 1, 2, 6, 12, 24	No difference in visual analog scale score between BP and NS.
Akoglu <i>et al.</i> , 2006 (46)	BP: 6.0±2.5 NS: 6.1±1.6	BP: 16 (6 F, 10 M) NS: 15 (6 F, 9 M)	Turkey	Children's Hospital of Eastern Ontario pain scale, post-operative morbidity	0.25, 1, 4, 12, 16, 24	Significant reduction in Children's Hospital of Eastern Ontario pain scale scores and comorbidities in BP as compared to NS.
Kaygusuz and Susaman, 2003 (49)	BP: 9±2.7 NS: 8±2.6	BP: 20 (7 F, 13 M) NS: 20 (9 F, 11 M)	Turkey	Visual analog scale, post-operative morbidity	1, 3, 7	Reductions in visual analog scale scores and morbidities in BP as compared to NS.
Johansen <i>et al.</i> , 1996 (48)	BP: 25 NS: 23	BP: 9 (5 F, 4 M) NS: 10 (6 F, 4 M)	Denmark	Visual analog scale	0, 24, 48, 72, 96, 120, 144, 168, 192, 226, 240	Significant reduction in visual analog scale scores in BP as compared to NS.
Stuart <i>et al.</i> , 1994 (50)	BP: 6.4 NS: 6.0	BP: 21 (9 F, 12 M) NS: 21 (12 F, 9 M)	UK	Visual analog scale	0, 0.16, 1, 4, 24	No difference in visual analog scale scores between BP and NS.
Jebeles <i>et al.</i> , 1992 (47)	BP: 7.5±3.1 NS: 8.2±2.9	BP: 20 (7 F, 13 M) NS: 20 (9 F, 11 M)	USA	Visual analog scale	0, 24, 48, 72, 96, 120	No difference in visual analog scale scores between BP and NS.




Figure 4. Forest plot for studies evaluating the perceived level of pain between groups receiving either bupivacaine or normal saline 24 h post-tonsillectomy. The weighted effect size is presented as boxes and 95% CIs are presented as horizontal lines. A negative effect represents a reduction in the perceived level of pain for patients receiving bupivacaine during tonsillectomy; a positive effect represents a reduction in the perceived level of pain for patients in the placebo group receiving normal saline during tonsillectomy.




Figure 5. Forest plot for studies evaluating the mean duration of the tonsillectomy procedure between groups receiving either bupivacaine or normal saline. The weighted effect size is presented as boxes and the 95% CIs are presented as horizontal lines. A negative effect represents a reduced duration of the tonsillectomy procedure for patients receiving bupivacaine; a positive effect represents a reduced duration of the tonsillectomy procedure for patients in the placebo group receiving normal saline.

of the tonsillectomy procedure as compared to the effect of normal saline (g, -1.36; 95% CI, -2.44 to -0.27; P=0.01) with negligible heterogeneity (I², 6.4%).

Post-operative morbidity. A total of 5 studies compared post-operative morbidity of patients receiving tonsillectomy between the bupivacaine and control groups (32,33,45,46,49). An across-group random-effects analysis (Fig. 6) revealed a small negative and insignificant effect of bupivacaine to reduce post-operative morbidity as compared with that in the normal saline group (g, -0.23; 95% CI, -0.65 to 0.19; P=0.3) with no heterogeneity (I², 0%).

Discussion

The present review provided a comprehensive update on intra-operative and post-operative outcomes after administration of bupivacaine. It was demonstrated that the bupivacaine

administration during tonsillectomy was associated with a reduction of the perceived level of pain, shorter mean duration of the operation and a decrease in the incidence of post-operative morbidities as compared to the effects of normal saline application.

Due to the complex anatomy of the pharyngeal segments and their prominent vasculature, tonsillectomy represents a challenge for otolaryngologists worldwide (54,55). The traumatic nature of the procedure increases the likelihood of widespread intra-operative and post-operative morbidities (18,30,31,33). To counteract these side effects, bupivacaine has been increasingly recommended during tonsillectomies due to its superior antinociceptive properties and its ability to reduce vascular permeability and inflammation (22-24,48). A review from 1978 by Babst and Gilling (56) suggested that bupivacaine has a high affinity towards neural tissue and acts by inhibiting the onset of action potentials by obstructing Na⁺ ion transmission through the neural membrane, and by binding Ca²⁺ ion sites in the




Figure 6. Forest plot for studies evaluating the post-operative morbidity rate between groups receiving either bupivacaine or normal saline during tonsillectomy. The weighted effect size is presented as boxes and 95% CIs are presented as horizontal lines. A negative effect represents a reduced incidence of post-operative morbidity for patients receiving bupivacaine during tonsillectomy; a positive effect represents an increased incidence of post-operative morbidity for patients in the placebo group receiving normal saline during tonsillectomy.

external lipid layer to interfere with the mobility of phosphate groups. Other studies have indicated that the vascular permeability reduction and vasodilation properties of bupivacaine may help prevent the post-operative morbidity associated with tonsillectomy (57,58). In agreement with these studies, the present meta-analysis also suggested that bupivacaine use is associated with beneficial effects after tonsillectomy. Haksever *et al* (32) compared the effects of adjunct administration of 0.5% topical bupivacaine hydrochloride with the administration of normal saline during tonsillectomy and observed a significant reduction in the perceived level of pain from five hours post-surgery till the sixth day of follow-up, and a substantial reduction in the incidence of post-operative morbidities such as trismus, nausea, vomiting and otalgia until the fourth day of follow-up post-tonsillectomy. Similarly, another study reported a significant reduction in the levels of post-tonsillectomy morbidity, including halitosis, fever, nausea, vomiting and otalgia, for the group receiving bupivacaine hydrochloride as compared to the rates in the placebo group (33). The study also indicated that post-operative morbidities were significantly lower during the first, second and the fourth days of follow-up, and a significant reduction in the perceived level of pain between groups from five hours post-tonsillectomy until the sixth day of follow-up was achieved (33). Comparison of the efficacy of bupivacaine and lidocaine suggested that bupivacaine was associated with a significant reduction in post-tonsillectomy morbidities (33). In accordance with the above, the results of the present meta-analysis further confirmed the efficacy of bupivacaine, and a large and significant effect size reduction in the perceived level of post-tonsillectomy pain (Hedge's g, -1.48) was determined in the bupivacaine vs. the placebo group. Furthermore, a small effect size reduction in the onset of post-operative morbidities (-0.23) was obtained in the bupivacaine vs. the control group.

The present analysis also indicated that the use of bupivacaine reduced the incidence of intra-operative complications associated with tonsillectomy. A large effect size reduction in the mean duration of the tonsillectomy operation (-1.36) was observed with the use of bupivacaine as compared to the use of normal saline. In the published literature, a proportional association exists between the duration of an operative procedure and the amount of intra-operative

blood loss (59,60), which eventually leads to post-operative morbidities and prolongs the post-surgery recovery period. Collateral incisional damage to palatine, pharyngeal and tonsillar branches of the facial arteries are common during tonsillectomies due to the vascular organization of the tonsillar and the peri-tonsillar arch (61). These accidental incisions may increase the volume of intra-operative hemorrhages, prolong the recovery time after tonsillectomy and result in post-operative complications (61,62). Under such circumstances, the use of bupivacaine may limit intra-operative blood loss, thereby reducing the onset of post-operative morbidities.

Previous studies reported that the use of bupivacaine was associated with an improvement of the hematological outcomes, such as hemoglobin levels. A study included in our review reported an elevation in the level of hemoglobin in a pediatric population undergoing tonsillectomy with bupivacaine (12.1 ± 0.6 mg/dl) as compared to the level in the placebo group (10.8 ± 0.6 mg/dl) (29). The authors concluded that the improvement of hematological outcomes reflects the vasoconstrictive properties of bupivacaine, and at the same time, provides a prophylactic benefit against intra-operative and post-operative hemorrhagic complications, which may require blood transfusions in the pediatric population (63).

Of note, the present review and meta-analysis had certain limitations. First, the systematic review was not registered in a prospective registry such as PROSPERO and this may raise questions regarding the validity of the review (64). Furthermore, no subgroup analyses were performed on the specific doses of bupivacaine used in the studies, which may potentially impact the development of efficient otolaryngologic care guidelines for the optimal use of bupivacaine during tonsillectomies. Future studies should address this issue by performing meta regression-based analyses associating the effects of different dosages of bupivacaine during tonsillectomies. In addition, due to the paucity of the available data, the effectiveness of bupivacaine was not compared between pediatric and adult populations and the results cannot provide recommendations for specific populations. For the same reason, the patients' well-being outcomes, such as patient comfort and quality of life, were not assessed. Hence, further studies addressing these issues are required. The results will assist in developing robust

decision-making models for otolaryngologists to be able to choose ideal interventions and provide high-quality care for their patients.

In conclusion, the present systematic review and meta-analysis provided evidence at the level 1b supporting the use of bupivacaine during tonsillectomy to shorten the duration of the procedure. In addition, bupivacaine reduced the level of post-operative pain and the incidence of associated morbidities. The present results have implications for developing best-practice otolaryngologic care strategies for performing tonsillectomy operations.

Acknowledgements

Not applicable.

Funding

No funding received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

JW conceived and designed the study. NW and FG collected the data and performed the analysis and the interpretation of the data. JW was involved in the writing of the manuscript. All authors approved the final manuscript for publication, and agreed to be accountable for all aspects of the work and ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable

Patient consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests

References

1. Archer NM, Forbes PW, Dargie J, Manganella J, Licameli GR, Kenna MA and Brugnara C: Association of blood type with postsurgical mucosal bleeding in pediatric patients undergoing tonsillectomy with or without adenoidectomy. *JAMA Netw Open* 3: e201804, 2020.
2. Matera E, Di Domenicantonio R, Baglio G, Marchisio P, Perletti L, Lispi L, Mele A and Guasticchi G: Epidemiology of tonsillectomy and/or adenoidectomy in Italy. *Pediatr Med Chir* 26: 179-186, 2004.
3. Roushdy MM, Abdel-Ghaffar HS, Mohammed MA and Khalifa AH: Comparative study between the effect of Diclofenac and Ketorolac in post-tonsillectomy pain management. *Egypt J Neck Surg Otorhinolaryngol* 6: 43-53, 2020.
4. Di Luca M, Iannella G, Montevecchi F, Magliulo G, De Vito A, Cocuzza S, Maniaci A, Meccariello G, Cammaroto G, Sgarzani R, *et al*: Use of the transoral robotic surgery to treat patients with recurrent lingual tonsillitis. *Int J Med Robot* 16: e2106, 2020.
5. Soaper AL, Richardson ZL, Chen JL and Gerber ME: Pediatric tonsillectomy: A short-term and long-term comparison of intracapsular versus extracapsular techniques. *Int J Pediatr Otorhinolaryngol* 133: 109970, 2020.
6. Joseph M, Reardon E and Goodman M: Lingual tonsillectomy: A treatment for inflammatory lesions of the lingual tonsil. *Laryngoscope* 94: 179-184, 1984.
7. Krishna P and Lee D: Post-tonsillectomy bleeding: A meta-analysis. *Laryngoscope* 111: 1358-1361, 2001.
8. Broadman LM, Patel RI, Feldman BA, Sellman GL, Milmoie G and Camilon F: The effects of peritonsillar infiltration on the reduction of intraoperative blood loss and post-tonsillectomy pain in children. *Laryngoscope* 99: 578-581, 1989.
9. Teker AM, Korkut AY, Gedikli O and Kahya V: Prospective, controlled clinical trial of Ankaferd Blood Stopper in children undergoing tonsillectomy. *Int J Pediatr Otorhinolaryngol* 73: 1742-1745, 2009.
10. Kargi E, Hoşnüter M, Babuççu O, Altunkaya H and Altinyazar C: Effect of steroids on edema, ecchymosis, and intraoperative bleeding in rhinoplasty. *Ann Plast Surg* 51: 570-574, 2003.
11. Wohlgenuth PR and O'Brien GR: Postoperative edema in maxillofacial surgery; prevention and treatment with promethazine. *Am J Surg* 94: 537-541, 1957.
12. Xu F, Zeng W, Mao X and Fan GK: The efficacy of melilotus extract in the management of postoperative ecchymosis and edema after simultaneous rhinoplasty and blepharoplasty. *Aesthetic Plast Surg* 32: 599-603, 2008.
13. Davidoss NH, Eikelboom R, Friedland PL and Santa Maria PL: Wound healing after tonsillectomy - a review of the literature. *J Laryngol Otol* 132: 764-770, 2018.
14. Deutsch ES and Isaacson GC: Tonsils and adenoids: An update. *Pediatr Rev* 16: 17-21, 1995.
15. Linden BE, Gross CW, Long TE and Lazar RH: Morbidity in pediatric tonsillectomy. *Laryngoscope* 100: 120-124, 1990.
16. Odhagen E, Stalfors J and Sunnergren O: Morbidity after pediatric tonsillectomy versus tonsillectomy: A population-based cohort study. *Laryngoscope* 129: 2619-2626, 2019.
17. Nikandish R, Maghsoodi B, Khademi S, Motazedian S and Kaboodkhani R: Peritonsillar infiltration with bupivacaine and pethidine for relief of post-tonsillectomy pain: A randomised double-blind study. *Anaesthesia* 63: 20-25, 2008.
18. Sun J, Wu X, Meng Y and Jin L: Bupivacaine versus normal saline for relief of post-adenotonsillectomy pain in children: A meta-analysis. *Int J Pediatr Otorhinolaryngol* 74: 369-373, 2010.
19. Furutani K, Ikoma M, Ishii H, Baba H and Kohno T: Bupivacaine inhibits glutamatergic transmission in spinal dorsal horn neurons. *Anesthesiology* 112: 138-143, 2010.
20. Paganelli MA and Popescu GK: Actions of bupivacaine, a widely used local anesthetic, on NMDA receptor responses. *J Neurosci* 35: 831-842, 2015.
21. Block L, Jörneberg P, Björklund U, Westerlund A, Biber B and Hansson E: Ultralow concentrations of bupivacaine exert anti-inflammatory effects on inflammation-reactive astrocytes. *Eur J Neurosci* 38: 3669-3678, 2013.
22. Cassuto J, Sinclair R and Bonderovic M: Anti-inflammatory properties of local anesthetics and their present and potential clinical implications. *Acta Anaesthesiol Scand* 50: 265-282, 2006.
23. Anderson LA, Engel GM, Bruckner JD, Stoddard GJ and Peters CL: Reduced blood loss after total knee arthroplasty with local injection of bupivacaine and epinephrine. *J Knee Surg* 22: 130-136, 2009.
24. Metaxotos NG, Asplund O and Hayes M: The efficacy of bupivacaine with adrenaline in reducing pain and bleeding associated with breast reduction: A prospective trial. *Br J Plast Surg* 52: 290-293, 1999.
25. Kuthiala G and Chaudhary G: Ropivacaine: A review of its pharmacology and clinical use. *Indian J Anaesth* 55: 104-110, 2011.
26. Polley LS, Columb MO, Naughton NN, Wagner DS and van de Ven CJ: Relative analgesic potencies of ropivacaine and bupivacaine for epidural analgesia in labor: Implications for therapeutic indexes. *Anesthesiology* 90: 944-950, 1999.
27. Spivey WH, McNamara RM, MacKenzie RS, Bhat S and Burdick WP: A clinical comparison of lidocaine and bupivacaine. *Ann Emerg Med* 16: 752-757, 1987.

28. Abdel Raheem AG and Farouk ZM: Effect of preincisional peritonsillar infiltration of bupivacaine on post-tonsillectomy pain. *Egypt J Neck Surg Otorhinolaryngol* 5: 40-46, 2019.
29. Ergil J, Akkaya T, Gozaydin O, Gunsoy B, Alicura S, Aladag E, Gumus H and Akin I: Vasoconstrictive and analgesic efficacy of locally infiltrated levobupivacaine in tonsillectomy patients. *Int J Pediatr Otorhinolaryngol* 76: 1429-1433, 2012.
30. Junaid M, Halim MS, Onali MA, Qadeer S, Khan HU and Ali NS: Intraoperative use of analgesics in tonsillar fossa and postoperative evaluation with visual analogue scale scores-A prospective, randomized, placebo-controlled, double-blind clinical trial. *Int Arch Otorhinolaryngol* 24: e62-e67, 2020.
31. Ozkiriş M, Kapusuz Z and Saydam L: Comparison of ropivacaine, bupivacaine and lidocaine in the management of post-tonsillectomy pain. *Int J Pediatr Otorhinolaryngol* 76: 1831-1834, 2012.
32. Haksever M, Özmen S, Akduman D and Solmaz F: Topical bupivacaine compared to bupivacaine infiltration for post-tonsillectomy pain relief in children: A prospective randomized controlled clinical study. *Eur Arch Otorhinolaryngol* 271: 2555-2559, 2014.
33. Özmen OA and Özmen S: Topical bupivacaine compared to lidocaine with epinephrine for post-tonsillectomy pain relief in children: A randomized controlled study. *Int J Pediatr Otorhinolaryngol* 75: 77-80, 2011.
34. Tuhanioglu B and Erkan SO: Tonsillectomy pain control with IV dexamethasone, infiltrated dexamethasone and infiltrated bupivacaine; a randomised, double-blind, placebo controlled, prospective clinical trial. *J Pak Med Assoc* 68: 1002-1008, 2018.
35. Moher D, Liberati A, Tetzlaff J and Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Med* 6: e1000097, 2009.
36. Jørgensen L, Paludan-Müller AS, Laursen DR, Savović J, Boutron I, Sterne JA, Higgins JP and Hróbjartsson A: Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: Overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. *Syst Rev* 5: 80, 2016.
37. Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters M, Santaguida PL, Shamliyan T, Singh K, Tsertsvadze A, *et al*: Assessing the risk of bias of individual studies in systematic reviews of health care interventions. In: *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. Agency for Healthcare Research and Quality (US), Rockville, MD, 2008.
38. Burns PB, Rohrich RJ and Chung KC: The levels of evidence and their role in evidence-based medicine. *Plast Reconstr Surg* 128: 305-310, 2011.
39. Bax L, Yu LM, Ikeda N and Moons KG: A systematic comparison of software dedicated to meta-analysis of causal studies. *BMC Med Res Methodol* 7: 40, 2007.
40. Higgins JP, Thompson SG and Spiegelhalter DJ: A re-evaluation of random-effects meta-analysis. *J R Stat Soc Ser A Stat Soc* 172: 137-159, 2009.
41. Rosenthal R: Parametric measures of effect size. In: *The Handbook of Research Synthesis*. Russell Sage Foundation, New York, NY, pp231-244, 1994.
42. Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. *Stat Med* 21: 1539-1558, 2002.
43. Petitti DB: Approaches to heterogeneity in meta-analysis. *Stat Med* 20: 3625-3633, 2001.
44. Duval S and Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 56: 455-463, 2000.
45. Karaaslan K, Yilmaz F, Gulcu N, Sarpkaya A, Colak C and Kocoglu H: The effects of levobupivacaine versus levobupivacaine plus magnesium infiltration on postoperative analgesia and laryngospasm in pediatric tonsillectomy patients. *Int J Pediatr Otorhinolaryngol* 72: 675-681, 2008.
46. Akoglu E, Akkurt BC, Inanoglu K, Okuyucu S and Dagli S: Ropivacaine compared to bupivacaine for post-tonsillectomy pain relief in children: A randomized controlled study. *Int J Pediatr Otorhinolaryngol* 70: 1169-1173, 2006.
47. Jebeles JA, Reilly JS, Gutierrez JF, Bradley EL Jr and Kissin I: The effect of pre-incisional infiltration of tonsils with bupivacaine on the pain following tonsillectomy under general anesthesia. *Pain* 47: 305-308, 1991.
48. Johansen M, Harbo G and Illum P: Preincisional infiltration with bupivacaine in tonsillectomy. *Arch Otolaryngol Head Neck Surg* 122: 261-263, 1996.
49. Kaygusuz I and Susaman N: The effects of dexamethasone, bupivacaine and topical lidocaine spray on pain after tonsillectomy. *Int J Pediatr Otorhinolaryngol* 67: 737-742, 2003.
50. Stuart JC, MacGregor FB, Cairns CS and Chandrachud HR: Peritonsillar infiltration with bupivacaine for paediatric tonsillectomy. *Anaesth Intensive Care* 22: 679-682, 1994.
51. Unal Y, Pampal K, Korkmaz S, Arslan M, Zengin A and Kurtipek O: Comparison of bupivacaine and ropivacaine on postoperative pain after tonsillectomy in paediatric patients. *Int J Pediatr Otorhinolaryngol* 71: 83-87, 2007.
52. Sedgwick P: Meta-analyses: How to read a funnel plot. *BMJ* 346: f1342, 2013.
53. Terrin N, Schmid CH and Lau J: In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. *J Clin Epidemiol* 58: 894-901, 2005.
54. Bangera A: Anaesthesia for adenotonsillectomy: An update. *Indian J Anaesth* 61: 103-109, 2017.
55. Verma R, Verma RR and Verma RR: Tonsillectomy-comparative study of various techniques and changing trend. *Indian J Otolaryngol Head Neck Surg* 69: 549-558, 2017.
56. Babst CR and Gilling BN: Bupivacaine: A review. *Anesth Prog* 25: 87-91, 1978.
57. Iida H, Watanabe Y, Dohi S and Ishiyama T: Direct effects of ropivacaine and bupivacaine on spinal pial vessels in canine. Assessment with closed spinal window technique. *Anesthesiology* 87: 75-81, 1997.
58. Newton DJ, McLeod GA, Khan F and Belch JJ: Vasoactive characteristics of bupivacaine and levobupivacaine with and without adjuvant epinephrine in peripheral human skin. *Br J Anaesth* 94: 662-667, 2005.
59. Prasad KC and Prasad SC: Assessment of operative blood loss and the factors affecting it in tonsillectomy and adenotonsillectomy. *Indian J Otolaryngol Head Neck Surg* 63: 343-348, 2011.
60. Yu CN, Chow TK, Kwan AS, Wong SL and Fung SC: Intra-operative blood loss and operating time in orthognathic surgery using induced hypotensive general anaesthesia: Prospective study. *Hong Kong Med J* 6: 307-311, 2000.
61. Nosulia EV: Peculiarities of blood supply of palatal tonsils and the potential risk of hemorrhage during tonsillectomy: The literature review and case report. *Vestn Otorinolaringol* 1: 75-78, 2014 (In Russian).
62. Liu JH, Anderson KE, Willging JP, Myer CM III, Shott SR, Bratcher GO and Cotton RT: Posttonsillectomy hemorrhage: What is it and what should be recorded? *Arch Otolaryngol Head Neck Surg* 127: 1271-1275, 2001.
63. Mutz I and Simon H: Hemorrhagic complications after tonsillectomy and adenoidectomy. Experiences with 7,743 operations in 14 years. *Wien Klin Wochenschr* 105: 520-522, 1993 (In German).
64. PLoS Medicine Editors: Best practice in systematic reviews: The importance of protocols and registration. *PLoS Med* 8: e1001009, 2011.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.